{"id":34585,"date":"2016-10-27T12:40:29","date_gmt":"2016-10-27T04:40:29","guid":{"rendered":"http:\/\/www.chinamoneynetwork.com\/?p=56851"},"modified":"2016-10-27T12:40:29","modified_gmt":"2016-10-27T04:40:29","slug":"qiming-backed-gan-lee-pharmaceuticals-attempts-second-try-at-domestic-ipo","status":"publish","type":"post","link":"https:\/\/www.chinalegalblog.com\/en\/2016\/10\/27\/qiming-backed-gan-lee-pharmaceuticals-attempts-second-try-at-domestic-ipo\/","title":{"rendered":"Qiming-Backed Gan &amp; Lee Pharmaceuticals Attempts Second Try At Domestic IPO"},"content":{"rendered":"<img width=\"560\" height=\"417\" src=\"http:\/\/www.chinamoneynetwork.com\/wp-content\/uploads\/ganlee.jpg\" class=\"attachment-large size-large wp-post-image\" alt=\"ganlee\" style=\"display: block; margin: auto; margin-bottom: 5px;\" srcset=\"http:\/\/www.chinamoneynetwork.com\/wp-content\/uploads\/ganlee.jpg 560w, http:\/\/www.chinamoneynetwork.com\/wp-content\/uploads\/ganlee-300x223.jpg 300w\" sizes=\"(max-width: 560px) 100vw, 560px\" \/>Gan &#038; Lee Pharmaceuticals, a Chinese bio-pharmaceutical company backed by Qiming Venture Partners and other investors, is seeking a domestic IPO to raise RMB1.5 billion (US$221 million) two years after its first attempt failed. Beijing-based Gan &#038; Lee was established in 1998 and focuses on researching and manufacturing recombinant human insulin and its analogues in [&#8230;]<p><br>Visit <a href=\"http:\/\/www.chinamoneynetwork.com\/\" title=\"China Money Network\"><b>ChinaMoneyNetwork.com<\/b><\/a> for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter <a href=\"http:\/\/www.twitter.com\/chinamoneypod\" title=\"Follow China Money Network on Twitter\">@chinamoneypod<\/a> subscribe to all episodes on <a href=\"http:\/\/www.itunes.com\/podcast?id=451002399\" title=\"Download and listen to China Money Podcast on iTunes\">iTunes<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" width=\"560\" height=\"417\" src=\"http:\/\/www.chinamoneynetwork.com\/wp-content\/uploads\/ganlee.jpg\" alt=\"ganlee\">Gan &amp; Lee Pharmaceuticals, a Chinese bio-pharmaceutical company backed by Qiming Venture Partners and other investors, is seeking a domestic IPO to raise RMB1.5 billion (US$221 million) two years after its first attempt failed. Beijing-based Gan &amp; Lee was established in 1998 and focuses on researching and manufacturing recombinant human insulin and its analogues in [&hellip;]<\/p>\n<p>Visit <a href=\"http:\/\/www.chinamoneynetwork.com\/\" title=\"China Money Network\"><b>ChinaMoneyNetwork.com<\/b><\/a> for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter <a href=\"http:\/\/www.twitter.com\/chinamoneypod\" title=\"Follow China Money Network on Twitter\">@chinamoneypod<\/a> subscribe to all episodes on <a href=\"http:\/\/www.itunes.com\/podcast?id=451002399\" title=\"Download and listen to China Money Podcast on iTunes\">iTunes<\/a>.<\/p>\n","protected":false},"author":151,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[194,1623],"tags":[5436,7593,5256],"class_list":["post-34585","post","type-post","status-publish","format-standard","hentry","category-news-chinese-law","category-venture-capital","tag-exits","tag-fund-news","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/34585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/users\/151"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/comments?post=34585"}],"version-history":[{"count":1,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/34585\/revisions"}],"predecessor-version":[{"id":34586,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/34585\/revisions\/34586"}],"wp:attachment":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/media?parent=34585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/categories?post=34585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/tags?post=34585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}